Inhaled corticosteroids in COPD: the final verdict is…
نویسندگان
چکیده
منابع مشابه
Inhaled corticosteroids in COPD
C hronic obstructive pulmonary disease (COPD) is arguably the most common chronic disease of the lungs at present and, by 2020, it will be the third leading cause of death worldwide. COPD is associated with a relentless decline in forced expiratory volume in 1 second (FEV1) and, in the later stages, the condition progresses to pulmonary hypertension and hypoxic respiratory failure. Few interven...
متن کاملInhaled corticosteroids in COPD
The importance of presenting absolute cell numbers when counting cells in biological samples is illustrated by the potentially misleading interpretation of data in the paper by Marco Confalonieri and colleagues. The authors concluded that, in addition to reduced sputum neutrophilia, the number of sputum macrophages increased significantly following treatment with inhaled beclomethasone dipropio...
متن کاملInhaled corticosteroids in COPD: the clinical evidence.
In this article, we focus on the scientific evidence from randomised trials supporting treatment with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD), including treatment with combinations of long-acting β-agonist (LABA) bronchodilators and ICS. Our emphasis is on the methodological strengths and limitations that guide the conclusions that may be drawn. The evidenc...
متن کاملInhaled corticosteroids in COPD: the case against.
hronic obstructive pulmonary disease (COPD), a disease that encompasses emphysema, chronic obstructive bronchitis and small airway obstruction and that is characterised by largely irreversible airflow obstruction, now affects around 10% of the population over the age of 40 yrs [1]. The sixth commonest global cause of death in 1990, currently fourth in developed countries, it is expected rise to...
متن کاملInhaled Corticosteroids in COPD: A Controversy
Inhaled corticosteroids (ICS) are now very widely used in high doses in the management of COPD patients. In sharp contrast to the situation in asthma, ICS provide little or no benefit in COPD patients and may have long-term detrimental effects. High doses of ICS fail to reduce disease progression or mortality, even when combined with a long-acting 2 -agonist (LABA). Several trials have demonstr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2018
ISSN: 0903-1936,1399-3003
DOI: 10.1183/13993003.01940-2018